Industry
Biopharma
Research, clinical and manufacturing data grows faster than any team can govern it. Congruity360 gives biopharma organizations visibility and control over unstructured data – protecting IP, satisfying regulators and reducing what you store.
Request a Demo
10+ yrs
Typical retention window for clinical and regulatory records
60–80%
Of research and operational data is redundant, obsolete or trivial
30%+
Annual growth in unstructured scientific and manufacturing data
PB scale
Instrument, imaging and sequencing output across sites
Science moves fast. Data governance rarely keeps up.
Biopharma organizations carry decades of regulated, high-value data across labs, partners and acquisitions – most of it unclassified and unowned.
Research Data Sprawl
Instrument output, imaging, sequencing files and lab notebooks accumulate across labs, sites and clouds with no shared inventory or ownership.
Validated & Regulated Records
GxP, 21 CFR Part 11, HIPAA and EMA requirements demand defensible retention and audit evidence for content that often sits in ungoverned file shares.
Intellectual Property Exposure
Formulations, trial data and partner content are among the most targeted assets in the industry, yet permissions are frequently broad and unreviewed.
M&A and Partner Data
Acquisitions, CRO and CDMO relationships bring inherited data estates with unknown contents, unclear obligations and duplicated records.
Turn a regulated data estate into
a governed advantage
Congruity360 gives biopharma teams the visibility, context and control to act on unstructured data across research, clinical, manufacturing and corporate environments.
Step 01
Discover
Inventory research, clinical, manufacturing and corporate data across labs, on-premises storage and cloud.
Step 02
Classify
Identify PHI, trial data, IP and GxP records – plus the stale and duplicate content that adds only cost and risk.
Step 03
Control
Tighten access to sensitive science and partner content, and isolate or remediate high-risk data.
Step 04
Govern
Apply retention, legal hold and disposition policies continuously, with evidence auditors and regulators accept.
What biopharma teams gain from
governed unstructured data
Less data in scope
Defensible reduction
Retire expired studies and duplicate instrument output so there is less to store, secure and produce.
Protected IP
Lower exposure
Find where formulations, trial data and partner content live and correct over-broad access.
Days, not months
Audit readiness
Answer inspection, legal hold and regulatory requests from a classified, searchable estate.
Lower storage spend
Optimized infrastructure
Tier or remove cold research data instead of buying capacity for content nobody uses.
AI-ready science
Trusted data for research AI
Give discovery and analytics teams curated, governed data sets instead of raw file shares.
Repeatable
Sustained governance
Keep policy applied as new studies, sites and acquisitions bring more data into the estate.
Pharmaceutical Inc.
secures data and reduces risk
Pharmaceutical Company cleaned up open access, enforced retention schedules and eliminated ROT data
Reduced infrastructure and backup costs, remediated open access issues and built an extensible governance foundation across cloud and on-prem environments.
Read the story
Pharmaceutical Inc.
Data Security & Records Management
Ready to Take Control of
Your Biopharma Data?
Start with a data assessment and see exactly what lives across your research, clinical and manufacturing environments.